Literature DB >> 8587282

Role of hypertension in chronic renal allograft dysfunction.

C E Sanders1, J J Curtis.   

Abstract

The damaging effects of essential hypertension and the central role of the kidney in its pathogenesis have long been recognized. Essential hypertension is the second leading cause of end-stage renal disease in the United States, with its prevalence increasing dramatically over the last decade. Similarly, the role of the transplanted kidney in the pathogenesis of hypertension has been demonstrated in animals and humans. Concerns over the inability of immunologic advancements to improve long-term allograft survival have focused attention on nonimmunologic factors, such as hypertension, and its contribution to chronic renal allograft injury. However, the complex nature of post-transplant hypertension has made it difficult to discern if its occurrence is the cause or the consequence of chronic allograft dysfunction. The possibility remains that, in many patients, the two processes are not mutually exclusive and coexist. Regardless, post-transplant hypertension negatively impacts long-term allograft and patient survival. Many questions regarding the etiology, optimal therapy and role of various growth factors in mediating the damaging effects of post-transplant hypertension remain unanswered and should serve as the focus for future studies.

Entities:  

Mesh:

Year:  1995        PMID: 8587282

Source DB:  PubMed          Journal:  Kidney Int Suppl        ISSN: 0098-6577            Impact factor:   10.545


  8 in total

Review 1.  Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Authors:  Daniel J Salzberg
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

2.  Toxicodynamic effects of ciclosporin are reflected by metabolite profiles in the urine of healthy individuals after a single dose.

Authors:  Jost Klawitter; Manuel Haschke; Christine Kahle; Colleen Dingmann; Jelena Klawitter; Dieter Leibfritz; Uwe Christians
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 3.  Assessment and management of hypertension in transplant patients.

Authors:  Matthew R Weir; Ellen D Burgess; James E Cooper; Andrew Z Fenves; David Goldsmith; Dianne McKay; Anita Mehrotra; Mark M Mitsnefes; Domenic A Sica; Sandra J Taler
Journal:  J Am Soc Nephrol       Date:  2015-02-04       Impact factor: 10.121

Review 4.  Pathomechanisms and the diagnosis of arterial hypertension in pediatric renal allograft recipients.

Authors:  R Büscher; U Vester; A-M Wingen; Peter F Hoyer
Journal:  Pediatr Nephrol       Date:  2004-11       Impact factor: 3.714

Review 5.  Hypertension in dialysis and kidney transplant patients.

Authors:  G V Ramesh Prasad; Marcel Ruzicka; Kevin D Burns; Sheldon W Tobe; Marcel Lebel
Journal:  Can J Cardiol       Date:  2009-05       Impact factor: 5.223

Review 6.  Approach and Management of Hypertension After Kidney Transplantation.

Authors:  Ekamol Tantisattamo; Miklos Z Molnar; Bing T Ho; Uttam G Reddy; Donald C Dafoe; Hirohito Ichii; Antoney J Ferrey; Ramy M Hanna; Kamyar Kalantar-Zadeh; Alpesh Amin
Journal:  Front Med (Lausanne)       Date:  2020-06-16

7.  Dietary Approach to Stop Hypertension (DASH) diet and risk of renal function decline and all-cause mortality in renal transplant recipients.

Authors:  Maryse C J Osté; António W Gomes-Neto; Eva Corpeleijn; Rijk O B Gans; Martin H de Borst; Else van den Berg; Sabita S Soedamah-Muthu; Daan Kromhout; Gerjan J Navis; Stephan J L Bakker
Journal:  Am J Transplant       Date:  2018-03-23       Impact factor: 8.086

8.  Mycophenolate mofetil: safety and efficacy in the prophylaxis of acute kidney transplantation rejection.

Authors:  Pranav Dalal; Monica Grafals; Darshika Chhabra; Lorenzo Gallon
Journal:  Ther Clin Risk Manag       Date:  2009-03-26       Impact factor: 2.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.